Accumulation of amyloid β (Aβ) oligomers in the brain is toxic to synapses and may play an important role in memory loss in Alzheimer disease. However, how these toxins are built up in the brain is not understood. In this study we investigate whether impairments of insulin and insulinlike growth factor1 (IGF1) receptors play a role in aggregation of Aβ. Using primary neuronal culture and immortal cell line models, we show that expression of normal insulin or IGF1 receptors confers cells with abilities to reduce exogenously applied Aβ oligomers (also known as ADDLs) to monomers. In contrast, transfection of malfunctioning human insulin receptor mutants, identified originally from patient with insulin resistance syndrome, or inhibition of insulin and IGF1 receptors via pharmacological reagents increases ADDL levels by exacerbating their aggregation. In healthy cells, activation of insulin and IGF1 receptor reduces the extracellular ADDLs applied to cells via seemingly the insulindegrading enzyme activity. Although insulin triggers ADDL internalization, IGF1 appears to keep ADDLs on the cell surface. Nevertheless, both insulin and IGF1 reduce ADDL binding, protect synapses from ADDL synaptotoxic effects, and prevent the ADDLinduced surface insulin receptor loss. Our results suggest that dysfunctions of brain insulin and IGF1 receptors contribute to Aβ aggregation and subsequent synaptic loss.
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issues in uncovering the molecular pathogenesis of the disease.
Aβ accumulation and aggregation could derive from overproduction or impaired clearance. Mutations of APP or presenilins 1 and 2, for example, are shown to cause overproduction of Aβ1-42 and amyloid deposits in the brain of early onset AD (18, 19) . Because early onset AD accounts for less than 5% of entire AD population, APP and presenilin mutations cannot represent a universal mechanism for accumulation/aggregation of Aβ in the majority of AD cases. With respect to clearance, Aβ is normally removed by both global and local mechanisms, with the former requiring vascular transport across the bloodbrain barrier (20, 21) and the latter via local enzymatic digestions by several metalloproteases, including neprilysin, insulindegrading enzyme (IDE), and endothelin converting enzymes 1 and 2 (22) (23) (24) .
The fact that insulin is a common substrate for most of the identified Aβdegrading enzymes has drawn attention of investigators to roles of insulin signaling in Aβ clearance. Increases in insulin levels frequently seen in insulin resistance may compete for these enzymes and thus contribute to Aβ accumulation. Indeed, insulin signaling has been shown to regulate expression of metalloproteases such as IDE (25, 26) , and influence aspects of Aβ metabolism and catabolism (27) . In the endothelium of the brainblood barrier and glial cells, insulin signaling is reported to regulate proteinprotein interactions in an uptake cascade involving low density lipoprotein receptorrelated protein and its ligands ApoE and α2macroglobulin, a system known to bind and clear Aβ via endocytosis and/or vascular transport (28, 29) . Similarly, circulating IGF1 has been reported to play a role in Aβ clearance probably via facilitating brainblood barrier transportation (30, 31) .
In the brain, insulin signaling plays a role in learning and memory (32) (33) (34) , potentially linking insulin resistance to AD dementia. Recently we and others have shown that Aβ oligomers interact with neuronal insulin receptors to cause impairments of the receptor expression and function (35) (36) (37) . These impairments mimic the Aβ oligomerinduced synaptic long term potentiation inhibition and can be overcome by insulin treatment (35, 38) . Consistently, impairments of both IR and IGF1R have been reported in the AD brain (39) (40) (41) .
Based on these results, we ask whether impairment of insulin and IGF1 signaling contribute to Aβ oligomer buildup in brain cells. To address this question, we set out to test roles of IR and IGF1R in cellular clearance and transport of Aβ oligomers (ADDLs) applied to primary neuronal cultures and cell lines overexpressing IR and IGF1R. Our results show that insulin and IGF1 receptors function to reduce Aβ oligomers to monomers, and prevent Aβ oligomerinduced synaptic toxicity both at the level of synapse composition and structure. By contrast, receptor impairments resulting from "kinasedead" insulin receptor mutations, a tyrosine kinase inhibitor of the insulin and IGF1 receptor, or an inhibitory IGF1 receptor antibody increase ADDL aggregation in the extracellular medium. Our results provide cellular evidence linking insulin and IGF1 signaling to amyloidogenesis.
EXPERIMENTAL PROCEDURES
Primary cortical and hippocampal neuronal cultures were prepared from either postnatal day1 (P1) or embryonic day 18 (E18) rats according to previous descriptions (8, 37) . Neurons were maintained for ∼3 weeks before experimentation. NIH3T3 cells with or without expression of fulllength IR or IGF1R were cultured in low glucose (1 g/liter glucose) Dulbecco's modified Eagle's medium supplement with 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were cultured to ∼80% confluence and serum deprived overnight before using for experimental treatments. All cell culture media and reagents were purchased from Invitrogen (Carlsbad, CA).
The fulllength of human IR and "kinasedead" IR mutant constructs (42-44) were transiently transfected, respectively, into NIH3T3 cells and primary neurons using Lipofectamine 2000 (Invitrogen). Following transfection (3 h), cells were maintained for 48 h before ADDLs were prepared with synthetic Aβ1-42 (American Peptides, Sunnyvale, CA) according to the procedure described previously (45) . For certain experiments, biotin labeled synthetic Aβ1-42 was used to prepared ADDLs (bADDLs) using the above protocol (7) . Cultured neurons and IR or IGF1Rexpressing cells were treated with 100 nM ADDLs or vehicle at 37 °C for various times in the presence or absence of 100 nM insulin or 100 nM IGF1. To inhibit IR and IGF1R activities, cells were pretreated with 100 μM AG1024 for 45 min before ADDL or insulin/IGF1. A second dose of AG1024 was given together with ADDLs, and/or insulin/IFG1. A neutralizing IGF1R antibody (1:50, MAB391, R&D Systems, Minneapolis, MN) was also preincubated with neurons for 15 min to inhibit the IGF1R activity. After ADDL treatments for different lengths of time, the culture media were collected, and spun at 4,000 rpm for 10 min to remove cell debris. The media were then concentrated using Centricon YM3 (Millipore, Temecula, CA). To prepare cell lysates, the treated cells were rinsed with 1× PBS, quick frozen then lysed on ice for 30 min in a lysis buffer (10 mM TrisHCl, pH 7.4, 150 mM NaCl, 0.8 M EDTA, 0.5 M EGTA, 1% Triton X100, 0.5% Nonidet P40, and 1% protease cocktails). The lysates were then centrifuged at 10,000 × g for 15 min, and the supernatant was collected. Protein concentrations were determined and equalized before samples were applied to dot and Western blotting.
ADDL levels were measured with dot and Western blots. For dot blotting, the concentrated media and cell lysates from different treatments were spot, in triplicates, onto a nitrocellulose membrane. For Western blotting, the concentrated media were resolved on 4-20% SDSPAGE and transferred to a nitrocellulose membrane. The ADDL immunoreactivity was determined with NU1 (1:2000) or NU2 (1:4000) antibodies (46) followed by a chemiluminescent detection process.
Primary neurons or NIH3T3 cells transfected with wildtype or mutant human insulin receptors were treated with 100 nM bADDLs for 30 min in the presence or absence of 100 nM insulin. Upon termination of the treatments, the media were collected and concentrated with Centricon YM3. bADDLs from the concentrated media were pulled down by 6E10 that was immobilized to agarose resin (AminoLink Plus Coupling Resin, Pierce). The precipitated bADDLs were separated on 4-20% SDS PAGE and transferred to a nitrocellulose membrane. The bADDL signals were then detected with streptavidin conjugated with horseradish peroxidase followed by chemiluminescent process.
Surface insulin receptor biotinylation was performed using the surface labeling kit (Pierce) according to the manufacturer's manual. The isolated surface and the total insulin receptors were resolved on 4-20% SDSPAGE and transferred to nitrocellulose membranes. The amount of receptors was detected with polyclonal antibodies against the α subunit of the insulin receptor. Changes in the amount of surface receptor were measured after normalization with the total amount of receptors in each sample prior to bead pull down.
ADDL ELISA was performed in a 96well Optiplate (PerkinElmer) coated with NU1 (5 μg/ml) in a carbonatebicarbonate buffer. After blocking with 5% bovine serum albumin (SigmaAldrich), the ADDLtreated media and cell lysate samples were added to each well (100 μl/well) in quadruplicates, and incubated at 4 °C overnight. The unbound samples were removed and plate washed six times with PBS containing Tween 20 (PBST) at room temperature. A 6E10 antibody (100 ng/ml) conjugated with alkaline phosphate was added to each well (100 μl/well) and incubated at room temperature for 2 h. After washes with PBST, the plate was incubated with the CDPStar substrate (Applied Biosystems, Foster City, CA) at room temperature for 30 min. The ELISA signal was read on an Envision microplate platform (PerkinElmer Life Sciences).
Immunocytochemical staining were performed as described previously (8, 37) . Briefly, the treated neurons and NIH3T3 cells were fixed with 3.7% formaldehyde at room temperature for 10 min. Following washes with PBS, pH 7.5, blocking/permeabilizing with 10% normal goat serum containing 0.1% Triton X100, cells were incubated with either NU1 (1:500) or 6E10 (1:200) to detect
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Insulin Signaling Reduces Extracellular ADDLs ADDL binding. A neuronal marker (an antiGAP43 antibody or fluorescentlabeled cholera toxin B), was simultaneously present in the incubation. The IRexpressing cells were double stained with NU1 (1:500), an antiIR antibody (1:200) . In the experiments where the surface IR expression was measured, immunolabeling was performed without permeabilizing reagent. In some experiments, biotinlabeled ADDLs (bADDL) were used to treat neurons. To identify astrocytes, an antiglial fibrillary acidic protein antibody was used. The incubations were carried out overnight at 4 °C. Cells were washed three times with PBS and incubated for 1 h at room temperature with appropriate Alexa fluorophoreconjugated secondary antibodies (1:500). After wash, cells on coverslips were mounted with Prolong Gold mounting medium (Invitrogen) and were observed with Leica TCS SP2 confocal or Nikon TE 1200 fluorescence microscopes.
The ADDLinduced dendritic spine loss was measured as described previously (8) . In brief, 21 days in vitro hippocampal neurons were treated with vehicle or ADDLs (500 nM) for 24 h in the presence or absence of 1 μM insulin or different concentration (0.1, 0.5, and 1.0 μM) IGF1. Changes in spine abundance were determined by the immunoreactivity of drebrin, a specific dendritic spine marker, using drebrin antibody (1:500, Stressgen, Victoria, British Columbia, Canada) overnight at 4 °C followed by AlexaFluor488conjugated secondary antibody incubation. Data obtained from three independent experiments, using three dendritic regions from five individual images containing ADDLtargeted neurons, were quantified with the Metamorph v6.3 software (Universal Imaging Corp., Downingtown, PA). The density of dendritic spines was quantified by the number of drebrinpositive puncta per length of dendrite.
For each experiment, at least three independent replicated experiments were performed. ADDL immunoreactive results from dot and Western blots were acquired with densitometric scan and quantified with ImageJ. The values from triplicates of each treatment from at least three repeated experiments were compared statistically using GraphPad Prism software (San Diego, CA). ADDL binding on neuronal dendritic processes were also quantified with ImageJ and analyzed with 1way analysis of variance. For spine densities, the quantified values from Metamorph were analyzed statically by GraphPad Prism using Oneway analysis of variance and comparison posthoc tests.
RESULTS
To maintain ADDLs in their native form, we used dot blotting to measure ADDL levels in the medium and cortical cell lysates. Samples from ADDLtreated and control neurons were spotted on nitrocellulose membrane and blotted by a specific ADDL antibody, NU2. NU2 showed negative immunoreactivity with samples from vehicle and insulintreated cortical cells (Fig. 1A, 1  and 2 ), but detected a strong immunoreactivity from samples (both medium and lysates) treated with 100 nM ADDLs (Fig. 1A3) . A brief (5min) insulin stimulation caused a reduction of ADDLs in the medium alone with an increase in ADDLs in the lysates (Fig. 1A4 ). In contrast, AG1024, an IR and IGF1R tyrosine kinase inhibitor (47) , caused a striking increase in ADDL immunoreactivity in the medium, but a marked decrease in ADDL reactivity in the cell lysate (Fig. 1, A5 and A6). Similar results were also observed with cultured hippocampal neurons (data not shown). A time course study (Fig. 1B) showed that there was an initial reduction in extracellular ADDL immunoreactivity shortly (30 min) after addition to cells (Fig. 1B1) . It was then gradually increased as incubation time was prolonged, probably due to continuous aggregation of unbound ADDL species in the medium. In the cell lysate (Fig. 1B2 ) the highest ADDL immunoreactivity was seen immediately after its addition to cells, indicating a rapid binding. The immunoreactivity was reduced by 40% at 24 h after ADDL incubation. Addition of insulin reduced the extracellular ADDL buildup, which was accompanied by an increase in ADDL immunoreactivity in the cell lysate at 30 and 60 min after ADDL incubation. At 24 h after incubation, however, insulin caused a marked reduction in both extra and intracellular ADDLs.
To verify that the observed ADDL reduction was due to functions of IR, we tested ADDL clearance in
Insulin Resistanceassociated IR Mutation Causes Increases in Extracellular ADDL Levels

IGF1R Functions to Reduce ADDLs in the Extracellular Compartment
Impairments of IR and IGF1R Promote Extracellular ADDL Aggregation
NIH3T3 cells with or without IR overexpression. In cells with absence of IR (3T3IR (−)), the majority of ADDL immunoreactivity was present in the medium (Fig. 1C1) suggesting a low level ADDL binding. Insulin and AG1024 treatments had no effect on ADDL levels. In contract, cells with stable overexpression of the human IR (3T3IR (+)) showed transfer of ADDL from medium to the cell lysates following insulin stimulation (Fig. 1C2) , which was inhibited by AG1024. Together, these results suggest that activation of IR promoted transport of ADDLs from medium to cell lysates, which appeared to be associated with ADDL clearance.
To verify effects of IR activity on ADDL reduction, we transiently infected 3T3 IR (−) cells or neuronal cultures with human wildtype or two "kinase dead" human IR mutations. The first IR mutation was a naturally occurring tyrosine kinasedeficient insulin receptor mutation (42, 43) , in which methionine at position 1153 was replaced by isoleucine (Met → Ile). The second was also a human insulin receptor gene with mutation on the ATPbinding site (44) by replacing lysine at position 1030 with alanine (Lys → Ala). Patients with these mutations have impaired insulin receptor functions manifested as obesity, diabetes, and other insulin resistance syndrome (42) (43) (44) . As shown in Fig. 2A , when transfected into NIH3T3 cells, all IR constructs expressed the IR protein at similar levels (upper panel), except for the eGFP construct, a negative control. However, only the wildtype IR displayed tyrosine phosphorylation in the β subunit in response to insulin (lower panel, indicated by an asterisk).
When treated with ADDLs ( Fig. 2B ), cells transfected with the wildtype IR showed a moderate level of ADDLs in the medium. Insulin caused a smaller decrease in extracellular bADDL levels, compared with results observed with stable IRexpressing cells in Fig. 1D . This discrepancy could be due to the low transfection efficiency in lipidbased method, such that the lower IR expression resulted in weaker ADDL binding and insulininduced effect. With IR mutant transfection, however, the extracellular ADDL levels rose by 1.5to greater than 2fold (Fig. 2B) . Similar results were also found in neurons transfected with IR mutants, in which the extracellular ADDL levels were increased by 2fold (Fig. 2C1) . Western blotting showed increased oligomeric species in the medium, including dimer, trimer, tetramer, and a higher band above 52 kDa (Fig. 2C3 ). In the cell lysates (Fig. 2C2) , insulin stimulated an increased ADDL signal. The insulinstimulated effect was not seen in neurons transfected with IR mutants Met → Ile and Lys → Ala, although the latter showed increased bADDL levels in the cell lysates regardless of insulin treatment. These results confirm the results in Fig. 1 , and clearly show that malfunctioning insulin receptors cause increases in ADDL species in the extra and/or intracellular compartments.
In the brain, the IR tetramer exists frequently as hybrids of IR and IGF1R, the latter also responding to insulin. We thus tested the involvement of IGF1R in ADDL cellular clearance. Unlike insulin, IGF1 did not increase the ADDL immunoreactivity in the lysate fraction of cortical neurons (Fig. 3A4) . It caused, however, a profound reduction in ADDL reactivity in the medium (Fig. 3, A and D4 ), which was also blocked by AG1024 (  Fig. 3A6) . When present alone, the AG1024increased extracellular ADDLs was accompanied by a reduction in intracellular ADDLs, probably due to inhibition of basal insulin receptor action (Fig. 2A5) . Similarly, in human IGF1Roverexpressing NIH3T3 (NIH3T3 IGF1R (+)) cells, IGF1 completely eliminated the extracellular ADDL immunoreactivity (Fig. 3B4) . These results suggest IGF1R is more effective in ADDL clearance compared with IR. Unlike IR, activation of which mediates ADDL attachment to cells, IGF1R activation appears to clear ADDLs using an extracellular mechanism.
To verify that the increased detectable ADDLs on dot blots under IR and IGF1 inhibition represents oligomers rather than monomers, we measured SDSresistant ADDL species using Western blots. As shown in Fig. 4A , the majority of ADDLs in the neuronal extracellular media were reduced to monomers (lane 2), that further decreased in the presence of insulin and IGF1 (lanes 3-6) . Several high molecular bands resistant to SDS were also shown 9) along with a reduction in monomers. Insulin and IGF1 lost effects in the presence of AG1024. In addition, treatment of cortical cultures with a neutralizing IGF1R antibody, known to inhibit the activity of IGF1R (48) , also caused increases in ADDL aggregates in the medium, although to a lesser degree (lane 10). When incubated in cellfree conditioned neurobasalA with or without 100 μM AG1024, ADDL did not show the massive aggregation (lanes 11-12) , excluding the possibility of ADDLcompound direct interaction. Thus, inhibition of IR or IGF1R accelerates aggregation of Aβ oligomers that accumulate in the extracellular compartment.
IR Mediates Internalization of ADDLs in NIH3T3IR(+) Cells
To assess ADDLs species in the intracellular portion (include the cytosol and the membrane) after insulin and IGF1 treatment, we used immunoprecipitation to isolate ADDLs from the cell lysates followed by Western blots (Fig. 4B) When incubated with NIH3T3 IR (−) cells (Fig. 4C1) , ADDLs from the medium were resolved as monomers and some high molecular weight aggregated species (lane 2). No difference was observed with insulin treatment (lane 3). In the presence of AG1024, an additional band above 52kDa was detected (lane 4). Interestingly a similar band was also observed in the medium of the kinasedead IR mutantstransfected neurons (Fig. 2C2) . When ADDLs were applied to NIH3T3IR(+) (Fig. 4C2 ) and IGF1R(+) cells (  Fig. 4C3) , however, not only were no high ADDL aggregates detectable, the amount of Aβ monomer was also markedly reduced (Fig. 4, C2 and 3, lane 2) . Stimulation of cells with insulin further reduced the amount of Aβ (Fig. 4, C2 and 3, lane 3) clearly consistent with the dot blotting results. AG1024 again caused a massive increase in ADDL aggregates that are much stronger than those from normal 3T3 cells (  Fig. 4, C2 and 3, lane 4) , demonstrating that the aggregation is specifically associated with impairment of IR or IGF1R. Collectively, these results suggest that activation of IR and IGF1R can reduce the extracellular ADDLs to monomers. The proper functions of IR and IGF1R are important to prevent aggregation of Aβ in the extracellular compartment.
Because insulin induced a translocation of ADDL immunoreactivity to intracellular compartments, we tested whether this was due to internalization of ADDLs. Clear ADDL binding was detected in NIH3T3IR(+) cells (Fig. 5B2) , suggesting an interaction between ADDL and IR while no ADDL binding was shown in parent NIH3T3 cells which had no IR and IGF1R expression (Fig. 5, 1A) . On the other hand, a brief insulin stimulation (5 min) induced a high ADDL binding and translocation of ADDL immunoreactivity into the intracellular compartments (Fig. 5B  3) . The internalized ADDLs were highly colocalized with IR suggesting complex of ADDLs with activated IR. Because the images were acquired via confocal sequential scanning, the colocalization of the immunosignals could not result from filter "bleedthrough." The internalized ADDLs were highly compartmentalized suggesting that the oligomers were transported via a specific pathway. Under prolonged insulin treatment (30 min), the internalized ADDLs and IR traveled further to the nuclear envelop and the nucleus (Fig. 5B4) . We next compared the insulininduced ADDL internalization in the IR and IGF1Rexpressing cells. The immunoreactivity of ADDLs, IR, and IGF1R were observed under an epifluorescent microscope. Unlike NIH3T3IR(+) cells (Fig. 5C, upper panel, 2) , the binding of ADDLs was relatively sparse in NIH3T3IGF1R(+) cell (Fig. 5C, lower panel, 2) . While insulin stimulated ADDL internalization to the nucleus of the IRexpressing cells (upper 3), ADDLs were not
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internalized by insulin into the IGF1Rexpressing cells, but stuck on the membrane surface (lower 3). In the presence of AG1024, ADDL uptake to the IRexpressing cells was blocked, with extracellular aggregation of ADDLs observed in both types of cells (Fig. 5C4) . These results indicate that, whereas activation of IR promotes internalization of ADDLs, activation of IGF1R appears to keep ADDLs on the membrane surface. The attachment of ADDLs on the membrane surface may probably explain the appearance of ADDLs in the cell lysates in neuronal cultures following IGF1 stimulation (see Fig. 4B ).
In cultured neurons, ADDL binding was detected by NU1 on dendrites (Fig. 6A, panel 5 and 6 ). Following treatment of insulin for 10 min and 1 h, ADDL binding was significantly (p < 0.001) reduced (Fig. 6A, panels 7 and 8) . The decreased binding occurred largely in dendrites proximate to the soma, and was accompanied by an increase in ADDL immunostaining inside the cell body (Fig. 6A, panels 8 and 9 ). In comparison, 6E10 detected internalized ADDLs in both neuronal and nonneuronal cells under insulin treatment (Fig. 6B1,  panels 8 and 9 ). Fig. 6B2 shows quantification of the NU1detected ADDL dendritic binding under insulin treatments. In addition, IGF1 also reduced ADDL binding to dendrites (data not shown).
To verify the expression of IR in the ADDLcontaining cells, we double stained the bADDLtreated, and permeabilized neurons with an IRα antibody followed antirabbit IgG conjugated with Alexa488 and streptavidin conjugated with Alexa555. Under this permeabilized condition, both surface and internal IRα would be measured. As shown in Fig. 6C , IR was expressed in normal neurons, including dendrites and the soma. When treated with bADDLs, IR only showed a low degree of colocalization (yellow colored, arrows in Fig. 6D1 , Merge) with ADDL binding, probably due to its rapid loss from the surface upon ADDL treatment (37) . Indeed, in some neurons, the majority of the IR signals was present inside the ADDL bound dendrites (Fig. 6D1, merge) , whereas other neurons showed more severe dendritic IRα loss (Fig. 6  D2, merge, arrowhead) . In addition, abundant IR immunoreactive was seen in astrocyteslike cells adjacent to the neuron (Fig. 6D2, arrow) that appeared to take up bADDLs. To verify whether uptake of ADDLs occurs in astrocytes under insulin and IGF1 treatments, we double stained the bADDLtreated hippocampal neurons in the presence or absence of insulin or IGF1 with an antiglial fibrillary acidic protein antibody, an astrocyte marker, and the antiADDL antibody NU1 (Fig. 6E) . Although a low degree of ADDL binding was observed on astrocytes (Fig. 6E, upper left panel) , insulin triggered an increase in ADDL signal in the cell body and processes of astrocytes Fig. 6E (upper middle panel) . In contract, IGF1 did not induce significant ADDL internalization into astrocytes, although an increased amount of ADDL staining was detected on the membrane of those cells (Fig. 6E, upper right panel) . Similar results were also seen with bADDLs: insulin clearly stimulated translocation of bADDLs to the intracellular compartment of astrocytes. The internalized bADDLs were localized in the perinuclear or intranuclear areas (Fig. 6E, lower right panel) , similar to those observed in Fig. 5 . Collectively, these results indicate that internalization of ADDLs in nervous cells is promoted by insulin.
To test whether the insulininduced ADDL internalization is harmful to synapses, we test effects of insulin on ADDLinduced synaptic spine loss. As previously reported, ADDLs have a deleterious effect on dendritic spine expression (8) . Using immunocytochemistry of drebrin, a cytoskeletal marker highly concentrated in dendritic spine heads, we applied a long term ADDL treatment (500 nM, 24 h) to hippocampal neurons in the presence or absence of 1 μM insulin and different concentrations of IGF1. Relative drebrin immunofluorescence was quantified and expressed as number of drebrin positive puncta per length of dendrite, which was measured on images, including full neurons that presented ADDLs bound to their dendrites. As shown in Fig. 7A , vehicle (VEH)treated neurons harbored abundant dendritic spine densities. However, a drastic loss (∼85%) in drebrinpositive puncta was observed after ADDL incubation (Fig. 7A1 , AD, p < 0.001). IGF1 showed a concentrationdependent protection of drebrin: at 1 μM it prevented the ADDLinduced drebrin loss (Fig. 7A1, ADIGF1) . No significant effects were observed at 0.1 μM (Fig. 7A1, ADIGF0.1) , and a partial prevention was afforded by 0.5 μM IGF1 (data not shown). Similarly, 1 μM insulin (Fig. 7A1, AD (Fig. 7A  1, VEHIGF0.1 and VEHIGF1 ) and insulin on their own (Fig. 7A1, VEHINS1) did not seem to have a major impact on spine drebrin expression. A statistical comparison of spine drebrin levels under different treatments were summarized in Fig. 7A2 .
Insulin and IGF1induced ADDL Degradation Is Inhibited by IDE Inhibitor Phenanthroline Expressions of IR and IGF1R Confer on Cells the Capability to Reduce ADDLs to Monomers
Furthermore, we tested the protective effect of IGF1 and insulin on ADDLinduced surface IR loss. The surface IR was imaged on ADDLtreated hippocampal neurons without permeabilization. As shown in Fig. 7B , both IGF1 and insulin at 1 μM completely protected the dendritic surface IRα from ADDLs. These effects were confirmed by surface biotinylation (Fig. 7C) . Taking together, although differences exist in ADDL internalization in response to insulin or IGF1, these results clearly demonstrate both insulin and IGF1 prevents ADDLs from causing synaptic spine and the surface insulin receptor losses.
To understand the mechanism by which IGF1 cause ADDL clearance in the extracellular medium, we explored the involvement of IDE and neprilysin, two most extensively studied metallopeptidases known to play a role in cellular digestion of Aβ (49) (50) (51) . Cortical neurons were pretreated with an IDE inhibitor 1, 10 phenanthroline (52) and a neprilysin inhibitor phosphoramidon prior to ADDL, insulin, and IGF1 treatments. Levels of ADDLs from the medium and lysates were measured using ELISA. As shown in Fig. 8A , phosphoramidon markedly increased the extracellular ADDL levels, but it did not block effects of insulin and IGF1, implicating that insulin and IGF1 activated an alternative mechanism to reduce ADDLs. In contrast, although phenanthroline alone did not cause significant increases in extracellular ADDLs, it completely blocked the effect of IGF1, and to a lesser degree, of insulin. These results suggest that neprilysin plays a predominant role in ADDL degradation in the extracellular compartment. However, when it is inhibited, insulin and IGF1 compensate via different enzymes such as IDE. In the cell lysates, on the other hand, both phenanthroline and phosphoramidon caused increased ADDL levels suggesting inhibition of ADDL degradation (Fig. 8B) . By inhibiting degradation of Aβ monomers, phenanthroline and phosphoramidon may shift the oligomermonomer equilibrium toward higher oligomer levels. Interestingly, insulin did not cause further increase in intracellular ADDLs. Cells might increase ADDL internalization to compensate for the inhibition of extracellular ADDLs. In this case, any insulininduced ADDL internalization might be masked. However, further studies are required to clearly understand the cellular clearance of ADDLs.
DISCUSSION
Accumulation of neurotoxic soluble Aβ oligomers in the CNS appears to be responsible for synaptic damage in early stages of AD (10, 13, 53) . An important goal is to identify factors that may prevent or promote accumulation of these neurotoxins. A great deal of interest has been drawn to the role of insulin signaling in the etiology and pathogenesis of AD (54, 55) . Not only is the type 2 diabetes mellitus a risk factor for AD (56, 57) , but these two diseases also share several common molecular pathological features such as amyloidogenesis (1, (58) (59) (60) and insulin resistance (54, 60, 61) . Here we show that cultured nerve cells possess a capacity of degrading exogenously added ADDLs in a timedependent manner. The degradation in the extracellular milieu can be accelerated by activation of IRs and IGF1Rs. Conversely, dysfunctional IR mutants that manifest insulin resistance syndrome in clinic, or pharmacological inhibition of the receptor activities prevent ADDL removal and promote its further aggregation. These results provide compelling evidence linking insulin resistance to Aβ abnormality, strongly supporting the hypothesis that dysfunctional CNS insulin or IGF1 signaling may significantly contribute to the onset and progression of AD pathology (40, 41, 61, 62, 85, 86) .
ADDLs, added exogenously to culture medium, are poorly eliminated by cells without IR or IGF1R. However, cells overexpressing either of these receptors gained the capacity to decrease ADDL levels. A basal reduction in
Mechanisms by Which Insulin and IGF1 Mediate ADDL Degradation Protection of Dendritic Spines from ADDLs by Insulin and IGF1
ADDLs by transfected cells was readily detectable, but the elimination occurred more rapidly upon IR or IGFactivation. Our results demonstrate a cellular mechanism by which ADDLs and Aβ peptides can be eliminated locally. Neuronal cultures with endogenous IR and IGF1R expression also showed an ability to reduce ADDLs, although this was more moderate than the receptoroverexpressing cells, suggesting abundance of IRs and IGF1Rs influence ADDL clearance capability.
Our results showed that extracellular ADDLs levels were markedly increased by phosphoramidon, suggesting that neprilysin plays a major role in degrading the extracellular ADDLs. This is consistent with the membrane surface land presynaptic terminal localization of neprilysin (49, 63) . However, insulin and IGF1induced ADDL reduction was blocked only by phenanthroline, suggesting that the effects of insulin and IGF1 on ADDL reduction in the medium are mediated by IDE. IDE has been shown to reside in the detergentresistant membranes (64) and is transported to the extracellular domain via a distinct pathway (65) . It is therefore possible that insulin and IGF1 stimulate IDE secretion, which acts as a complementary mechanism for ADDL clearance in the extracellular compartment. Although IDE and neprilysin have been thought to be effective toward mainly Aβ monomers (66) (67) (68) , through degradation of monomers they may shift the equilibrium between monomers and soluble oligomers toward left. Although either insulin or IGF1 reduced ADDL levels, different characteristics were observed. IR activation produced increased ADDLs in cell lysate fractions and intracellularly, suggesting induced internalization. These patterns were not seen with IGF1R signaling, which retains ADDLs on the membrane surface. Thus the IGF1 induced ADDL clearance may occur mainly on the cell surface or in the extracellular matrix. Although IR and IGF1R respond to each other's ligand and share common structures, they activate distinct substrates and pathways (69) , which might determine their differences in interaction with ADDLs. These differences are consistent with previous observations that oligomers of Aβ bind to IRassociated complexes but not to IGF1Rs (37) . Insulin caused ADDL immunoreactivity to be translocated to specific intracellular loci, including the nucleus in both NIH3T3 IR(+) and mixed cortical cells. The internalization was accompanied by a reduction in ADDL binding to dendrites most notably when cells were sensitized to insulin by prior withdrawal of exogenous insulin from the medium. Overall, insulininduced ADDL internalization was observed more routinely in glialrich cultures prepared from postnatal rat brains. Although binding of ADDLs or Aβ to IR has been detected (35) (36) (37) , only a low degree of colocalization between IR and ADDL were seen in neuronal dendrites and astrocytes. This could be explained by rapid loss of the dendritic surface IR upon ADDL binding (37) . Intracellular accumulation of exogenously applied Aβ has been previously observed in other types of cells such as human skin fibroblasts (70) , although the mediating mechanism may be different. Although uptake is required for Aβ clearance in nonneuronal cells such as microglia and endothelium involving functions of LPR and its ligand ApoE and α2macroglobulin (29, 71, 72) , the nature and significance of insulininduced neuronal and astrocytes ADDL uptake remain to be understood.
ADDLs are known to cause significant deterioration of synaptic spines (8), a pathology expected to underlie cognitive failure in AD (10). Our results thus raise an important question: is insulininduced ADDL internalization harmful to synapses? We showed that, although insulin stimulated ADDL internalization, at the same time, it reduced ADDL binding to neurons, prevented the surface IR loss, and blocked ADDLinduced drebrin loss in dendritic spines. This finding is in harmony with previous reports showing insulin rescues the Aβ oligomerinduced long term potentiation impairment (35, 38) , and suggest that in the presence of insulin, internalized ADDLs failed to cause spine loss. Although it differs in ADDL internalization, IGF1 showed a similar efficacy to insulin in protecting the surface IR and the spine loss triggered by ADDLs. It is possible that these neuroprotective effects of insulin may involve activation of IGF1Rs, (or vice versa). IGF1 has been reported to protect neurons from Aβ (73, 74) . In behavioral studies, insulin and insulin sensitizers are known to improve cognitive performance both in AD patients and animals with AD pathology (75, 76) . The protection of spines by insulin against ADDLs may provide a mechanism at the synaptic level
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underlying the beneficial effect of insulin on long term potentiation in animal AD models and its memory enhancing effects in AD patients.
The current findings also reveal new pathogenic consequences of diminished brain cell insulin signaling. Converse to the ability of normal IR and IGF1Rs to mediate a robust clearance of ADDLs, cells with impaired IR and IGF1R activities show markedly reduced clearance capacity. Reduced ability to clear these potent CNS neurotoxin provides a mechanism that may account, at least in part, for indications that dysfunctional insulin and IGF1 signaling in the brain contributes to AD pathophysiology (1, 2, 5, 33, 35-37, 60 ).
An intriguing additional finding that is germane to the relationship between insulin resistance and Aβ abnormality is the altered oligomerization of Aβ occurring in the presence of cells with impaired IRs. Because there is no endogenous production of human Aβ from the cell types used, the increased ADDL immunoreactivity observed in all IR/IGF1R inhibitory conditions (expression of kinase dead IR mutation; inhibition of IR/IGF1R by AG1024; and inhibition of IGF1R by an inhibitory antibody) is due either to an overall increase in Aβ oligomerization or generation of highly immunoreactive oligomeric species. In pathological studies, both small oligomers (dimertetramer) and large oligomers (12mers) have been found in AD brain and AD mouse models (11, 12, 15, (77) (78) (79) (80) . The possibility exists that these different oligomers may instigate different neurological deficits associated with AD. Seen here, inhibition of IRs promotes accumulation of oligomers, including the 12mer range, which are pathogenic synaptic ligands (8) . Interestingly, in cells lacking IR and IGF1R, although ADDLs were not efficiently digested, no significant enhancement of aggregation or reorganization took place. This raises the interesting possibility that interactions of soluble forms of Aβ with dysfunctional IR and IGF1R might play a "gainoffunction" role in Aβ oligomerization, actively promoting protein misfolding and/or misassembly. Precedent that interactions between fibrillogenic proteins and cell surfaces can alter the nature of oligomerization was recently reported for human amylin oligomers, formation of which is linked to diabetes (58, 81) .
Recently, we and others have observed that Aβ oligomers downregulate IR function and surface expression, thereby causing brain cell insulin resistance (35) (36) (37) (38) . Thus, although normal IR activity helps to defend against the accumulation of toxic Aβ oligomers, the insulin receptors themselves are vulnerable to oligomerinitiated dysfunction. This relationship has the potential to generate an insidious pathogenic loop. Deficits in IR function, which could arise from multiple factors, would contribute to increased ADDL formation/accumulation in the brain, and the increasing ADDL levels would further suppress IR activity and worsen insulin insensitivity. It seems likely that the pathologically reinforcing loop between these two abnormalities exacerbate one another to drive the progression of the AD process, although it will require considerable effort to clarify the relationship in vivo. Given the potential of interactions between accumulation of Aβ oligomers and impairment of insulin/IGF1 signaling for driving disease progression, there may be a synergistic benefit to treating patients with drugs that enhance CNS insulin signaling in tandem with those that neutralize ADDLs. Steps toward each are now in progress individually (82) (83) (84) . The current results suggest further that understanding the precise relationship between IR/IGF1R signaling and APP processing/Aβ clearance may lead to identification of additional cellular targets for prevention and treatment of AD.
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